Article Text

Download PDFPDF
Ganglionic Local Opioid Application (GLOA) for Treatment of Chronic Headache and Facial Pain
  1. Clinton L. Harris, M.D.,
  2. Basem Hamid, M.D.,
  3. Richard W. Rosenquist, M.D. and
  4. Sebastian H.W. Schultz-Stubner, M.D.
  1. From the University of Iowa Department of Anesthesia, Iowa City, IA.
  1. Reprint requests: Basem Hamid, M.D., U.T.M.D. Anderson Cancer Center, Dept. of Anesthesiology and Pain Medicine-Unit 409, 1400 Holcombe Blvd., Houston, TX 77030-4009. E-mail: bhamid{at}


Objective: This report describes the effects of ganglionic local opioid application (GLOA) in patients with chronic headache and persistent idiopathic facial pain.

Case Report: We present 2 patients with chronic headaches and 1 patient with persistent idiopathic facial pain who were refractory to medical treatment. These patients responded well to a series of ganglionic local opioid applications (GLOAs) by administration of buprenorphine. The beneficial effect of GLOA was manifested by a decrease in pain intensity, reduction of pain medications, and improvement in quality of life.

Conclusions: These results support the theory of sympathetically mediated pain in the head and face, the presence of opioid receptors on the sympathetic ganglia, and a possible beneficial role of opioids in modulation of this process. To our knowledge, this case series is the first case series in the English literature of the use of GLOA at the stellate ganglion for head-and-face pain.

  • Buprenorphine
  • GLOA
  • Headache
  • Facial pain
  • Stellate ganglion

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Poster was presented at the American Society of Regional Anesthesia and Pain Medicine 2005 annual fall meeting, Miami, FL, November 17-20, 2005.